Navigation Links
Cellular Biomedicine Group Announces Expansion in the Osteoarthritis and Rheumatoid Arthritis Market
Date:6/13/2013

PALO ALTO, Calif., June 13, 2013 /PRNewswire/ -- Cellular Biomedicine Group, Inc. (OTCQB: CBMG), a biomedicine firm engaged in the development of new treatments for degenerative and cancerous diseases, today announced their anticipation of expansion in the China Osteoarthritis and Rheumatoid Arthritis market. A complete analysis of current China patents by an intellectual property law firm has rendered the legal opinion that Cellular Biomedicine Group has complete freedom of IP operation with regards to their patents for autologous and allogeneic adipose-derived stem cell compositions for the treatment of osteoarthritis and rheumatoid arthritis, as well as for various stem cell processing and preservation technologies.

Dr. Wei (William) Cao, President of Cellular Biomedicine Group, commented, "In China there are 72.5 Million people suffering from Knee Osteoarthritis (KOA), and 4.5 Million suffering from Rheumatoid Arthritis (RA). We are very confident to enter the world's largest KOA and RA market with freedom of operation."

About Cellular Biomedicine Group
Cellular Biomedicine Group, Inc. develops proprietary cell therapies for the treatment of certain degenerative diseases and cancers.  Our developmental stem cell, progenitor cell, and immune cell projects are the result of research and development by scientists and doctors from China and the United States. Our flagship GMP facility, consisting of eight independent cell production lines, is designed, certified and managed according to U.S. standards.  To learn more about CBMG, please visit:www.cellbiomedgroup.com

Forward-Looking Statements
Statements in this press release relating to plans, strategies, trends, specific activities or investments, and other statements that are not descriptions of historical facts may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking information is inherently subject to risks and uncertainties, and actual results could differ materially from those currently anticipated due to a number of factors, which include, but are not limited to, risk factors inherent in doing business. Forward-looking statements may be identified by terms such as "may," "will," "expects," "plans," "intends," "estimates," "potential," or "continue," or similar terms or the negative of these terms. Although CBMG believes the expectations reflected in the forward-looking statements are reasonable, they cannot guarantee that future results, levels of activity, performance or achievements will be obtained. CBMG does not have any obligation to update these forward-looking statements other than as required by law.

Contact:
Jeff Ramson 
Investor Relations
ProActive Capital Group
+1 646-863-6341

Sarah Kelly 
Director of Corporate Communications, CBMG
+1 650 566 5064
sarah.kelly@cellbiomedgroup.com


'/>"/>
SOURCE Cellular Biomedicine Group, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Cellular Therapy and Cord Blood 2013 Market Report
2. Cellular Biomedicine Group Announces Appointment of Corporate Controller
3. Cellular Dynamics International Expands MyCell Products Line with Disease Models, Genetic Engineering Patents
4. Cellular Dynamics International Files Registration Statement for Proposed Initial Public Offering
5. Cellular Biomedicine Group Achieves 50% Enrollment Milestone in Phase I Clinical Trial for Knee Osteoarthritis
6. Intra-Cellular Therapies Appoints Professor Sir Michael Rawlins to its Board of Directors
7. Top Genetic and Cellular Researchers Honored at ASGCT 16th Annual Meeting
8. Exit discovered in cellular garbage truck
9. ASGCT Annual Meeting to Highlight Latest Advances in Genetic and Cellular Therapeutics
10. Cellular Biomedicine Group Provides Update and 2013 Milestones
11. Unique Extracellular Matrix Used in Patient Successfully Treated for Flesh Eating Bacteria
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/18/2017)... ... May 16, 2017 , ... Clinical Supplies Management (“CSM”), a Great Point Partners ... to grow. CSM has doubled in size over the past six months with ... strategy. , Roger Gasper joins CSM as Chief Financial Officer. Roger has over ...
(Date:5/18/2017)... SANTA BARBARA, CALIFORNIA (PRWEB) , ... May 17, ... ... risk management, technological innovation and business process optimization firm for the life sciences ... the Chairman of the UDIs and Traceability for Medical Devices conference in Brussels, ...
(Date:5/18/2017)... ... May 18, 2017 , ... When James Sherley, was notified earlier this year that ... Brands for the Year 2017 by The Silicon Review , he was not surprised ... progress increasing Asymmetrex’s value, but this recognition by Silicon Valley was particularly meaningful. Our ...
(Date:5/16/2017)... , ... May 16, 2017 , ... ... and cancer diagnostics, has released its ClearID Lung Cancer blood test. Leveraging a ... cancer, this new test is designed to quickly and accurately identify tumor-related genetic ...
Breaking Biology Technology:
(Date:3/30/2017)... , March 30, 2017 The research team ... for three-dimensional (3D) fingerprint identification by adopting ground breaking 3D fingerprint ... new realm of speed and accuracy for use in identification, crime ... affordable cost. ... A ...
(Date:3/28/2017)... India , March 28, 2017 ... IP, Biometrics), Hardware (Camera, Monitors, Servers, Storage Devices), Software ... Vertical, and Region - Global Forecast to 2022", published ... Billion in 2016 and is projected to reach USD ... between 2017 and 2022. The base year considered for ...
(Date:3/24/2017)... , Mar 24, 2017 Research and Markets ... System Market Analysis & Trends - Industry Forecast to 2025" ... ... grow at a CAGR of around 15.1% over the next decade ... industry report analyzes the market estimates and forecasts for all the ...
Breaking Biology News(10 mins):